IL139502A0 - Combination of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer - Google Patents
Combination of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancerInfo
- Publication number
- IL139502A0 IL139502A0 IL13950299A IL13950299A IL139502A0 IL 139502 A0 IL139502 A0 IL 139502A0 IL 13950299 A IL13950299 A IL 13950299A IL 13950299 A IL13950299 A IL 13950299A IL 139502 A0 IL139502 A0 IL 139502A0
- Authority
- IL
- Israel
- Prior art keywords
- combination
- coa reductase
- reductase inhibitors
- treat cancer
- hmg coa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8520298P | 1998-05-12 | 1998-05-12 | |
| US9225398P | 1998-07-10 | 1998-07-10 | |
| PCT/US1999/010188 WO1999058505A2 (fr) | 1998-05-12 | 1999-05-10 | Combinaisons d'inhibiteurs de proteine farnesyltransferase et de hmg coa reductase et leurs utilisations dans le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL139502A0 true IL139502A0 (en) | 2001-11-25 |
Family
ID=26772425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13950299A IL139502A0 (en) | 1998-05-12 | 1999-05-10 | Combination of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6492410B1 (fr) |
| EP (1) | EP1077949A2 (fr) |
| JP (1) | JP2002514628A (fr) |
| KR (1) | KR20010043529A (fr) |
| CN (1) | CN1171874C (fr) |
| AP (1) | AP2000001984A0 (fr) |
| AU (1) | AU758891B2 (fr) |
| BG (1) | BG105003A (fr) |
| BR (1) | BR9911785A (fr) |
| CA (1) | CA2331295A1 (fr) |
| EA (1) | EA003860B1 (fr) |
| EE (1) | EE200000660A (fr) |
| GE (1) | GEP20032996B (fr) |
| HK (1) | HK1038355A1 (fr) |
| HR (1) | HRP20000771A2 (fr) |
| HU (1) | HUP0102322A3 (fr) |
| ID (1) | ID27933A (fr) |
| IL (1) | IL139502A0 (fr) |
| IS (1) | IS5713A (fr) |
| NO (1) | NO20005680L (fr) |
| NZ (1) | NZ508357A (fr) |
| OA (1) | OA11551A (fr) |
| PL (1) | PL344662A1 (fr) |
| SK (1) | SK16742000A3 (fr) |
| WO (1) | WO1999058505A2 (fr) |
| YU (1) | YU68900A (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2363088A1 (fr) * | 1999-02-11 | 2000-08-17 | Patrick T. Prendergast | Methodes pour traiter des infections virales |
| US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| US20020010128A1 (en) * | 2000-04-13 | 2002-01-24 | Parks Thomas P. | Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| US20020132781A1 (en) * | 2000-10-06 | 2002-09-19 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor |
| GB0220885D0 (en) * | 2002-09-09 | 2002-10-16 | Novartis Ag | Organic compounds |
| WO2005042710A1 (fr) * | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilisation de statines pour detruire des cellules b transformees par virus d'epstein-barr (veb) |
| KR101329112B1 (ko) * | 2005-11-08 | 2013-11-14 | 랜박시 래보러터리스 리미티드 | (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법 |
| KR100930365B1 (ko) * | 2006-11-09 | 2009-12-08 | 덕성여자대학교 산학협력단 | 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물 |
| US20080119444A1 (en) * | 2006-11-16 | 2008-05-22 | Steven Lehrer | Methods and compositions for the treatment of cancer |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK523288A (da) * | 1987-10-06 | 1989-04-07 | Hoffmann La Roche | Aminosyrederivater |
| NL9002031A (nl) | 1990-09-14 | 1992-04-01 | Voskuilen Woudenberg Bv | Inrichting voor het bewerken van een uitwendig buisoppervlak. |
| US5571792A (en) * | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
| JPH11508262A (ja) | 1995-06-22 | 1999-07-21 | バイオジェン，インコーポレイテッド | Ｃｄ４０リガンドのフラグメントの結晶およびその使用 |
| HUP9802821A3 (en) * | 1995-06-22 | 2000-03-28 | Novo Nordisk As | Compounds with growth hormone releasing properties |
| UA57081C2 (uk) * | 1997-06-16 | 2003-06-16 | Пфайзер Продактс Інк. | Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування |
-
1999
- 1999-05-10 EP EP99922898A patent/EP1077949A2/fr not_active Withdrawn
- 1999-05-10 JP JP2000548309A patent/JP2002514628A/ja active Pending
- 1999-05-10 OA OA1200000310A patent/OA11551A/en unknown
- 1999-05-10 YU YU68900A patent/YU68900A/sh unknown
- 1999-05-10 CN CNB99807649XA patent/CN1171874C/zh not_active Expired - Fee Related
- 1999-05-10 EE EEP200000660A patent/EE200000660A/xx unknown
- 1999-05-10 AU AU39792/99A patent/AU758891B2/en not_active Ceased
- 1999-05-10 GE GEAP19995670A patent/GEP20032996B/en unknown
- 1999-05-10 AP APAP/P/2000/001984A patent/AP2000001984A0/en unknown
- 1999-05-10 EA EA200001164A patent/EA003860B1/ru not_active IP Right Cessation
- 1999-05-10 KR KR1020007012632A patent/KR20010043529A/ko not_active Application Discontinuation
- 1999-05-10 WO PCT/US1999/010188 patent/WO1999058505A2/fr not_active Application Discontinuation
- 1999-05-10 SK SK1674-2000A patent/SK16742000A3/sk unknown
- 1999-05-10 US US09/674,818 patent/US6492410B1/en not_active Expired - Fee Related
- 1999-05-10 HU HU0102322A patent/HUP0102322A3/hu unknown
- 1999-05-10 IL IL13950299A patent/IL139502A0/xx unknown
- 1999-05-10 ID IDW20002583A patent/ID27933A/id unknown
- 1999-05-10 CA CA002331295A patent/CA2331295A1/fr not_active Abandoned
- 1999-05-10 PL PL99344662A patent/PL344662A1/xx not_active Application Discontinuation
- 1999-05-10 NZ NZ508357A patent/NZ508357A/xx unknown
- 1999-05-10 BR BR9911785-1A patent/BR9911785A/pt not_active IP Right Cessation
-
2000
- 2000-11-10 IS IS5713A patent/IS5713A/is unknown
- 2000-11-10 NO NO20005680A patent/NO20005680L/no not_active Application Discontinuation
- 2000-11-13 HR HR20000771A patent/HRP20000771A2/hr not_active Application Discontinuation
- 2000-11-29 BG BG105003A patent/BG105003A/xx unknown
-
2001
- 2001-12-27 HK HK01109123A patent/HK1038355A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EA003860B1 (ru) | 2003-10-30 |
| ID27933A (id) | 2001-05-03 |
| PL344662A1 (en) | 2001-11-19 |
| HUP0102322A3 (en) | 2001-12-28 |
| BG105003A (en) | 2001-07-31 |
| BR9911785A (pt) | 2001-04-03 |
| SK16742000A3 (sk) | 2001-07-10 |
| GEP20032996B (en) | 2003-06-25 |
| CA2331295A1 (fr) | 1999-11-18 |
| WO1999058505A2 (fr) | 1999-11-18 |
| HK1038355A1 (en) | 2002-03-15 |
| AU3979299A (en) | 1999-11-29 |
| KR20010043529A (ko) | 2001-05-25 |
| NO20005680D0 (no) | 2000-11-10 |
| OA11551A (en) | 2004-05-24 |
| EE200000660A (et) | 2002-04-15 |
| WO1999058505A3 (fr) | 2000-01-06 |
| HUP0102322A2 (hu) | 2001-11-28 |
| HRP20000771A2 (en) | 2001-06-30 |
| CN1171874C (zh) | 2004-10-20 |
| CN1306515A (zh) | 2001-08-01 |
| US6492410B1 (en) | 2002-12-10 |
| EP1077949A2 (fr) | 2001-02-28 |
| NO20005680L (no) | 2001-01-10 |
| IS5713A (is) | 2000-11-10 |
| YU68900A (sh) | 2002-12-10 |
| AU758891B2 (en) | 2003-04-03 |
| EA200001164A1 (ru) | 2001-06-25 |
| AP2000001984A0 (en) | 2000-12-31 |
| NZ508357A (en) | 2002-09-27 |
| JP2002514628A (ja) | 2002-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9903841D0 (en) | Diagnosis and treatment of cancer | |
| IL140845A0 (en) | Compositions for therapy and diagnosis of prostate cancer | |
| PL340643A1 (en) | Composition of aldosic reductase inhibitor and of glycogenic phosphorylase inhibitor | |
| IL189132A0 (en) | Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer | |
| AU2212299A (en) | Compositions and methods for the treatment of tumor | |
| AU7880700A (en) | Compositions and methods of treatment for skin conditions using extracts of turmeric | |
| AU3000297A (en) | Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy | |
| PL352931A1 (en) | Compositions and uses of et743 for treating cancer | |
| IL139502A0 (en) | Combination of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer | |
| HUP0002427A3 (en) | Leptin as an inhibitor of tumor cell proliferation and use of leptin | |
| AU6435398A (en) | Prevention and treatment of hepatocellular cancer | |
| AU3704800A (en) | Co-administration of lucanthone and radiation for treatment of cancer | |
| GB9808840D0 (en) | Treatment of depression and pharmaceutical preparations therefor | |
| NO996206D0 (no) | Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer | |
| IL127739A0 (en) | Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases | |
| AU2002313426A1 (en) | Tumor antigens for prevention and/or treatment of cancer | |
| IL141426A0 (en) | Compositions and methods for the treatment of tumor | |
| AU3270301A (en) | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity | |
| CZ20012029A3 (cs) | Přípravek se zlepąeným terapeutickým aplikačním rozsahem obsahující inhibitory nukleotidové syntézy | |
| GB9819999D0 (en) | Treatment of cancer | |
| AU2001297571A1 (en) | Detection and treatment of prostate cancer | |
| IL162760A0 (en) | Polyphenol inhibition of nucleosidediphosphate kinase-b activity and cancer | |
| PL337343A1 (en) | Method of obtaining drugs comprising inhibitors of hmg coa reductase | |
| SI0986387T1 (en) | FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| AU1471300A (en) | Compositions and methods for treatment of cancer |